Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.61 |
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.57 |
| ▸ | APP | P05067 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1099649 | 1.00 | MAPT (0.61) | MAPTNPC1GFERCYP19A1MAOA | |
| SCHEMBL9966009 | 0.87 | MAPT (0.65) | MAPTNPC1GFERSMN1; SMN2MEN1 | |
| SCHEMBL135604 | 0.87 | MAPT (0.65) | MAPTNPC1GFERSMN1; SMN2MEN1 | |
| SCHEMBL10459178 | 0.84 | CYP19A1 (0.78) | MAPTNPC1CYP19A1MAOAMAOB | |
| SCHEMBL7646748 | 0.84 | CYP19A1 (0.78) | MAPTNPC1CYP19A1MAOAMAOB | |
| SCHEMBL138489 | 0.84 | MAPT (0.61) | MAPTNPC1GFERCYP19A1SMN1; SMN2 | |
| SCHEMBL65443 | 0.84 | CYP19A1 (0.78) | MAPTNPC1CYP19A1MAOAMAOB | |
| SCHEMBL9680836 | 0.84 | CYP19A1 (0.78) | MAPTNPC1CYP19A1MAOAMAOB | |
| SCHEMBL65444 | 0.84 | CYP19A1 (0.78) | MAPTNPC1CYP19A1MAOAMAOB | |
| SCHEMBL107198 | 0.84 | MAPT (0.61) | MAPTNPC1GFERCYP19A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3674381-A1 | ORGANIC OPTICAL MATERIAL | Japan Science and Technology Agency (JP) | 2020-07-01 | — | — | EP | disclosed |
| US-10300155-B2 | Alpha-synuclein ligands | WASHINGTON UNIVERSITY (US) | 2019-05-28 | — | — | US | disclosed |
| US-9890187-B2 | Prototype systems of theranostic biomarkers for in vivo molecular management of cancer | EPOS-IASIS RESEARCH AND DEVELOPMENT, LTD. (CY) | 2018-02-13 | — | — | US | disclosed |
| US-9890187-B2 | Prototype systems of theranostic biomarkers for in vivo molecular management of cancer | EPOS-IASIS RESEARCH AND DEVELOPMENT, LTD. (CY) | 2018-02-13 | — | — | US | disclosed |
| US-20170189566-A1 | ALPHA-SYNUCLEIN LIGANDS | WASHINGTON UNIVERSITY (US) | 2017-07-06 | — | — | US | disclosed |
| US-20160376298-A1 | PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER | EPOS-IASIS RESEARCH AND DEVELOPMENT, LTD (CY) | 2016-12-29 | — | — | US | disclosed |
| US-8772048-B2 | Fluorogenic compounds converted to fluorophores by photochemical or chemical means and their use in biological systems | KENT STATE UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772048-B2 | Fluorogenic compounds converted to fluorophores by photochemical or chemical means and their use in biological systems | KENT STATE UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| US-20120190098-A1 | FLUOROGENIC COMPOUNDS CONVERTED TO FLUOROPHORES BY PHOTOCHEMICAL OR CHEMICAL MEANS AND THEIR USE IN BIOLOGICAL SYSTEMS | LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190098-A1 | FLUOROGENIC COMPOUNDS CONVERTED TO FLUOROPHORES BY PHOTOCHEMICAL OR CHEMICAL MEANS AND THEIR USE IN BIOLOGICAL SYSTEMS | LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-07-26 | — | — | US | disclosed |
| US-8153446-B2 | Fluorogenic compounds converted to fluorophores by photochemical or chemical means and their use in biological systems | KENT STATE UNIVERSITY (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100029952-A1 | Fluorogenic compounds converted to fluorophores by photochemical or chemical means and their use in biological systems | KENT STATE UNIVERSITY (US) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190098-A1 | FLUOROGENIC COMPOUNDS CONVERTED TO FLUOROPHORES BY PHOTOCHEMICAL OR CHEMICAL MEANS AND THEIR USE IN BIOLOGICAL SYSTEMS | MPI, ACR, PFAS | MAPT 2134/4885NPC1 3105/4885GFER 530/4885 |
| US-10300155-B2 | Alpha-synuclein ligands | SNCA, PARK7, LRRK2 | MAPT 58/4885NPC1 382/4885GFER 3408/4885 |
| US-20160376298-A1 | PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER | TP53, MKI67, FLT3 | MAPT 4308/4885NPC1 4408/4885GFER 4179/4885 |
| US-20100029952-A1 | Fluorogenic compounds converted to fluorophores by photochemical or chemical means and their use in biological systems | MPI, ACR, PFAS | MAPT 2134/4885NPC1 3105/4885GFER 530/4885 |
| US-20170189566-A1 | ALPHA-SYNUCLEIN LIGANDS | SNCA, PARK7, LRRK2 | MAPT 58/4885NPC1 382/4885GFER 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.